Companies in #Pulmonary Disease
Found 1 company operating in this sector.
Clinical-stage biotechnology company focused on advancing LAM-001, an investigational inhaled formulation of rapamycin (an mTOR inhibitor), for multiple pulmonary diseases. Formerly Quince Therapeutics, the company relaunched under the IRulya name in October 2026 following its merger with Orphai Therapeutics, and relocated its headquarters from South San Francisco, California to New Haven, Connecticut.